Innovent's PD-1 inhibitor leads to 68.4% ORR in Phase Ib for first-line NSCLC

Innovent Biologics Inc. (Suzhou, China) reported data from 19 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) in cohort D of a Chinese Phase Ib trial

Read the full 274 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE